Studies show that CYP2D6 genotype does not predict tamoxifen benefit
Two studies published March 6 in the Journal of the National Cancer Institute provide insights about the CYP2D6 genotype in postmenopausal breast cancer patients and represent a major step forward in understanding the usefulness of CYP2D6 testing for deciding whether or not a patient should receive adjuvant tamoxifen for treatment of early-stage breast cancer. Both studies found that CYP2D6 genotypes that were indicative of reduced activity of enzymes that metabolize tamoxifen did not predict clinical responsiveness to adjuvant tamoxifen therapy among postmenopausal women with early-stage breast cancer. One study also found that CYP2D6 genotypes of reduced enzyme activity were not linked with fewer tamoxifen-induced hot flushes in patients.
Adjuvant tamoxifen therapy decreases the risk of recurrence and mortality in women with hormone receptor-positive early-stage breast cancer. But tamoxifen is known to have a weak affinity for the estrogen receptor, and undergoes extensive metabolism by the CYP2D6 enzyme to form more potent active metabolites including 4-hydroxytamoxifen and endoxifen. As a result, pharmacogenetic testing of CYP2D6 polymorphisms to identify patients with reduced tamoxifen metabolism phenotypes has been recommended, as testing may predict a poorer response to tamoxifen therapy, to help with treatment decision-making. And studies have proposed that metabolic conversion of tamoxifen to endoxifen by CYP2D6 is essential for a patient to benefit from tamoxifen therapy, leading to a trend of CYP2D6 genotyping among patients.
In order to determine the association between CYP2D6 polymorphisms and breast cancer recurrence, Meredith M. Regan, ScD, IBCSG Statistical Center, in the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute in Boston and Brian Leyland-Jones, MD, Emory University School of Medicine in Atlanta and colleagues, obtained tumor tissues from postmenopausal breast cancer patients who participated in the Breast International Group (BIG) 1-98 trial between March 1998-May 2003 and received adjuvant tamoxifen and/or letrozole. They isolated DNA from these tissues, performed CYP2D6 genotyping, and based on the genotype combinations, categorized the CYP2D6 metabolism phenotypes as poor, immediate, and extensive metabolizers.
The researchers found that CYP2D6 phenotypes of reduced enzyme activity were not associated with worse disease control, but were associated with increased tamoxifen-induced hot flushes, contrary to the prevalent hypothesis. Hot flushes are a commonly-reported side effect from tamoxifen, and it has been suggested that women who do not experience hot flushes may not be getting the full benefit of the drug because their body does not metabolize it adequately (i.e. poor and intermediate metabolizers). They write, "Our results indicate that CYP2D6 metabolism phenotype is not the correct surrogate for predicting symptoms and outcome of tamoxifen-treated post-menopausal women .The relationship of tamoxifen metabolism with symptoms and disease control is not adequately understood."
In a second study, James M. Rae, Ph.D., of the Division of Hematology/Oncology at the University of Michigan Comprehensive Cancer Center and colleagues, examined postmenopausal, hormone receptor-positive early-stage breast cancer patients from the UK population of the Arimidex Tamoxifen, Alone or in Combination (ATAC) clinical trial who received tamoxifen or anastrazole and were genotyped for CYP2D6 variants. UGT2B7 was also genotyped due to its known gene product which inactivates endoxifen. Patients were assigned a CYP2D6 activity score based on the genotype, and classified as poor, intermediate, and extensive metabolizer phenotypes.
The researchers found that the CYP2D6 genotype showed no association with disease recurrence rates, and phenotypes indicating reduced CYP2D6 enzyme activity were not found to be connected with worse disease outcomes. The researchers also reference the results found in the BIG 1-98 trial, saying that, "Taken together, these represent a high level of evidence demonstrating that CYP2D6 genotyping should not be recommended for such patients and that there is no need to avoid CYP2D6 inhibitors in postmenopausal patients taking tamoxifen."
In an accompanying editorial, Catherine M. Kelly of the department of medical oncology at the Mater Misericordiae University Hospital in Dublin, and Kathleen I. Pritchard, of the department of medical oncology at the Odette Cancer Centre at Sunnybrook Health Sciences Centre in Toronto, note that, "Over the last 9 years, a great industry of CYP2D6 measurement has arisen." Furthermore, the FDA's Clinical Pharmacology Subcommittee has suggested that the tamoxifen label include information about the increased risk of breast cancer recurrence in CYP2D6 poor metabolizers taking tamoxifen. The editorialists question this suggestion. "Validation of predictive biomarkers is a complicated process," they write, adding, "For example CYP2D6 metabolism status would have little impact on tamoxifen benefit if the breast cancer was already de novo resistant to endocrine therapy, or the patient had a very low risk of recurrence and surgery alone was sufficient."
The editorialists also advocate "large confirmatory studies
.for decisions regarding the use of therapeutic agents," and "data from randomized clinical trials for clinical demonstration of associations between biomarkers and disease outcomes."
Journal reference: Journal of the National Cancer Institute
Provided by Journal of the National Cancer Institute
- Genetic variation of enzyme linked with outcomes for women receiving tamoxifen Oct 06, 2009 | not rated yet | 0
- Researchers: tamoxifen's power comes from endoxifen Dec 11, 2008 | not rated yet | 0
- Cough medicine could help doctors identify how breast cancer patients metabolize tamoxifen Nov 19, 2010 | not rated yet | 0
- Most Oncologists Feel New Genetic Test for Tamoxifen Sensitivity Not Ready for the Clinic Dec 11, 2009 | not rated yet | 0
- Toxicity of aromatase inhibitors may explain lack of overall survival improvement Aug 22, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013 Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
In recent years, microRNAs (miRNAs) and other non-coding RNAs are small molecules that help control the expression of specific proteins. In recent years they have emerged as disease biomarkers. miRNA profiles have been used ...
Cancer May 24, 2013 | not rated yet | 0
Cancer cells spread and grow by avoiding detection and destruction by the immune system. Stimulation of the immune system can help to eliminate cancer cells; however, there are many factors that cause the immune system to ...
Cancer May 24, 2013 | 5 / 5 (1) | 0
Researchers from London's Kingston University have begun a two-year study which could help prolong the lives of people with colorectal tumours.
Cancer May 24, 2013 | 5 / 5 (1) | 0
Transformative research from Western University has identified new hormones in the body which may suppress breast cancer and stimulate the regression of breast tumors.
Cancer May 24, 2013 | 5 / 5 (2) | 0
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Cancer May 24, 2013 | 5 / 5 (4) | 0
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
19 hours ago | 5 / 5 (5) | 5
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
19 hours ago | 5 / 5 (1) | 1
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
11 hours ago | not rated yet | 1
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
May 20, 2013 | 4.8 / 5 (31) | 9 |
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
19 hours ago | not rated yet | 0
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
19 hours ago | not rated yet | 0